Table 2.
A summary among males of the frequency of diagnosed specific delays in development in comparison with organic mercury exposure from Thimerosal-containing hepatitis B vaccine administration within the Vaccine Safety Datalink (VSD) database.
| Group examined | Number of males diagnosed with specific delays in development (%) | Number of males in the cohort | Relative risk (95% CI) | Attributable risk % (95% CI) | Population attributable risk % (95% CI) |
|---|---|---|---|---|---|
| Experiment IV | |||||
| 12.5 μg Organic mercury within the first mo | 567 (5.62) | 9514 | 1.231* (1.108–1.369) | 1.057 (0.508–1.61) | 7.965 (3.846–12.08) |
| 0 μg Organic mercury within the first mo | 771 (4.57) | 16,110 | |||
| Experiment V | |||||
| 25 μg Organic mercury within the first 2 mo | 568 (5.63) | 9525 | 1.223* (1.1–1.359) | 1.025 (0.4727–1.58) | 7.798 (3.614–11.98) |
| 0 μg Organic mercury within the first 2 mo | 758 (4.60) | 15,709 | |||
| Experiment VI | |||||
| 37.5 μg Organic mercury within the first 6 mo | 443 (6.00) | 6946 | 3.148* (1.974–5.018) | 4.091 (3.065–5.117) | 65.57 (50.13–81) |
| 0 μg Organic mercury within the first 6 mo | 18 (1.90) | 927 | |||
CI = confidence interval.
*
p < 0.001.